State of the Art Treatment for Depression
NeuroPrex Inc. is an award winning medical device company in Silicon Valley, funded by National Science Foundation SBIR and European Commission Horizon 2020.
NPX TMS device was highlighted among the best research, education and technology at the 2021 American Psychiatric Association (APA) Annual Meeting.
NeuroPrex NPX
NPX is a revolutionary wearable TMS device for treating drug-resistant major depression and PTSD. Patients are stimulated through the proprietary star-shaped electromagnetic coils embedded in a surface pain reduction™ shield layer to modulate nerve activities in brain and body tissues associated with depression, PTSD and other neurological diseases.
NeuroPrex advisors confirm the urgent and unmet need of NPX TMS devices to serve the psychiatric industry and military community, in an interview with APA-TV.
More than 31 interviews and questionnaires with the leading doctors from Stanford University's psychiatrist and neurologist network in the USA, and European Alliance Against Depression in Europe, confirm Neuroprex NPX solves doctor's unmet needs to treatment alternatives for depression.
TMS treatment relieves 50-70% of depression symptoms and prevents suicidal behavior lasting for 6 months
The therapeutic worldwide market for depression and anxiety disorder is huge, over $18.3B and is still underserved. These diseases are the most prevalent health problem in the European workforce, accounting for €100B cost every year, and costs the US economy $210B every year in lost productivity and healthcare expenses and a total lost of over $1 trillion, globally. Thirty-three million persons have major depression in the U.S., 30 million in Europe, 100 million in China, 57 million in India and 8 million in Japan. Drugs are the primary method for treating major depression but with inadequate efficacy. 30% of patients are drug resistant and many have developed severe side effects such as attempted suicide and heart disease after a long term use, which makes the condition even worse.
Recently, the COVID-19 disease pandemic has more than doubled calls to suicide hotlines nationwide. Timely mental healthcare is urgently needed for patients and healthcare professional directly affected by the COVID-19 outbreak. As scientists and governments worldwide continue to understand the long-term nature of this contagion, the implications on mental well-being toward living behavior change post the outbreak must be kept in mind. This includes the acceleration of telemedicine and remote therapy as a tangible alternative to onsite care. The most common treatment for clinical depression is antidepressant drugs. However, these drugs have a slow response, an inadequate success rate and all come with side effects. Following antidepressant drug treatment, only 40% of patients achieve complete remission, while for 30% of patients, the treatment is ineffective and coupled with side effects such as stroke, myocardial infraction, epilepsy/seizures and self injurious behavior.
Repetitive Transcranial Magnetic Stimulation (TMS) is an FDA-cleared treatment for drug-resistant depression that involves creating energy stimulation through electromagnetic coils in brain tissues associated with depression. TMS machine has been used for a growing number of drug resistant patients to relieve 50-70% of their depression symptom and it also eliminates suicidal behavior with a long lasting efficacy of up to 6 months.
Freedom from from depression!
Benefits of NeuroPrex
Improved effectiveness and efficacy
The state-of-the-art design and cutting-edge technology to serve the patients for all doctors at all clinics
Safe and Comfortable
NPX device is being engineered under stringent standards of FDA compliance and tested at a certified safe engineering laboratory to ensure hazard control and safe operations. NPX Surface Pain Reduction™ technology removes pain and provides freedom of movement for a patient's head and neck during treatment.
Affordable
An affordable subscription rate for unlimited use enables doctors to sustain their small clinic business without increasing much cost to deliver effective treatment.
Easy to use
Carry out the NPX therapy right from your clinic or home. Users can easily and accurately position the coils on the patient's head to complete the multiple therapeutic sessions and the efficacy can be increased by wearing NPX Shield. The doctors can use the NPX device in the convenience of their clinic without having to refer out the patients.
Remove Drug Dependency
NeuroPrex addresses a vast number of drug resistant patients, essentially removing insufficiency associated with drugs, such as dependency side-effects, and non-effectiveness.
Knowledge Acquisition
The product is designed to give immediate feedback from the system to healthcare professionals after each treatment session by connecting to the cloud.
Pain is the major side effect in current TMS therapy
For TMS Therapy 40% of patients treated with current TMS devices have side effects of severe headaches or scalp pain during or after treatment. Current TMS treatment and machine device units are expensive and must be performed by a specialized technician for coil positioning. Accessibility to TMS device is limited, available only in a few psychiatrist’s clinics and large hospitals.
NPX is the ultimate solution for against depression and PTSD
TMS devices are also effective at treating PTSD and other neurological disorders. Over 8 million Americans are affected by PTSD each year. PTSD is an unresolved healthcare problem in the military community. More than 20 military veterans commit suicide each day in the U.S. NPX is a ground-breaking TMS device, in combination with advanced telemedicine and cloud technology, which disrupts and simplifies current procedures for treating depression and PTSD, to immediately serve more doctors, patients and veterans in their comfortable, adaptable and natural setting.